NewAmsterdam Pharma Co. N.V. (NAMS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NewAmsterdam Pharma Co. N.V. (NAMS:NASDAQ), powered by AI.

Current Price
$30.19
P/E Ratio
-17.5
Market Cap
3.6B
Sector
Healthcare
What is the NewAmsterdam Pharma Co. N.V. stock price forecast?

NewAmsterdam Pharma Co. N.V. is currently trading at $30.19. View real-time AI analysis on Alpha Lenz.

What is NewAmsterdam Pharma Co. N.V. insider trading activity?

View the latest insider trading data for NewAmsterdam Pharma Co. N.V. on Alpha Lenz.

What is NewAmsterdam Pharma Co. N.V.'s P/E ratio?

NewAmsterdam Pharma Co. N.V.'s P/E ratio is -17.5.

NewAmsterdam Pharma Co. N.V.

NASDAQ · NAMS
$30.19-0.41(-1.34%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about NewAmsterdam Pharma Co. N.V.'s future dividend policy...
Alpha Chat Insight

NewAmsterdam Pharma Co. N.V. trades at a P/E of -17.5 (undervalued) with modest ROE of -28.3%.

Ask for details

Company Overview

NewAmsterdam Pharma Co. N.V. is a pharmaceutical company focused on the research, development, and commercialization of transformative therapies addressing cardiovascular diseases. The company's primary mission is to innovate in the cardiovascular space by introducing medications that meet the evolving needs of patients worldwide. Notably, NewAmsterdam Pharma is at the forefront of developing novel treatments aimed at reducing cardiovascular risk and improving patient outcomes. Operating within the life sciences sector, the company leverages advanced scientific research and development capabilities to push forward its pipeline of projects. By concentrating specifically on cardiovascular therapies, NewAmsterdam Pharma aims to significantly impact a critical area of healthcare that affects millions globally. In the financial markets, the company represents an essential player within the pharmaceutical industry, focused on addressing unmet medical needs. Its work has substantial implications for both the healthcare sector and broader economic landscapes, illustrating the importance of continuous innovation in tackling global health challenges.

CEODr. Michael Harvey Davidson FACC, Facp., M.D.
SectorHealthcare
IndustryBiotechnology
Employees68

Company Statistics

FY 2025

Profile

$3.58BMarket Cap
$22.50MRevenue
0.00Shares Out
68Employees

Margins

N/AGross
-976.47%EBITDA
-1002.90%Operating
-905.74%Pre-Tax
-905.74%Net

Valuation

-17.54P/E
5.23P/B
158.88EV/Sales
-14.04EV/EBITDA
-24.15P/FCF

Growth (CAGR)

-40.51%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.95%ROA
-28.29%ROE
-27.63%ROIC

Financial Health

$490.00MCash & Cash Equivalents
$-404.15MNet Debt
12.56%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

NewAmsterdam Pharma Co. N.V. (ticker: NAMS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 68 employees. Market cap is $3.6B.

The current price is $30.19 with a P/E ratio of -17.54x and P/B of 5.23x.

ROE is -28.29% and operating margin is -1002.90%. Annual revenue is $23M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
NewAmsterdam Pharma Co. N.V. (NAMS) Stock Forecast 2026 $30.19 — Price, Financials & Analyst Targets | Alpha Lenz